Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 05.10.2026 2 Aliment Pharmacol Ther 1 Clin Gastroenterol Hepatol 1 Gastroenterol Hepatol 8 Inflamm Bowel Dis 1 J Crohns Colitis 1 J Gastroenterol 1 Minerva Gastroenterol (Torino)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. PARIGI TL, Solitano V, Mekonnen HD, Yuan Y, et al
   Systematic Review: Inclusion of Patients With Difficult-to-Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies.
   Aliment Pharmacol Ther. 2026 Oct 1. doi: 10.1111/apt.70998.
   PubMed         Abstract available
   
   
2. BASTON-REY I, Rodriguez-Lago I, Barreiro-de Acosta M
   Editorial: Beyond the Matrix-Upadacitinib in Real-World Refractory Crohn's Disease.
   Aliment Pharmacol Ther. 2026 Sep 26. doi: 10.1111/apt.71019.
   PubMed        
   
   

   
   Clin Gastroenterol Hepatol

3. HUPE M, Ahuja D, Yeh KH, Patel SB, et al
   Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.
   Clin Gastroenterol Hepatol. 2026 Sep 29:S1542-3565(26)00723.
   PubMed         Abstract available
   
   

   
   Gastroenterol Hepatol

4. GAZTELU EL, Moraleja I, Arevalo JA, Perez AA, et al
   Porphyria in ulcerative colitis: two cases and a novel drug trigger.
   Gastroenterol Hepatol. 2026 Sep 30:502869. doi: 10.1016/j.gastrohep.2026.502869.
   PubMed        
   
   

   
   Inflamm Bowel Dis

5. WAN J, Zhang H, Yuan X, Ren Z, et al
   Comparative effectiveness and safety of upadacitinib versus vedolizumab in anti-TNF-exposed patients with ulcerative colitis.
   Inflamm Bowel Dis. 2026 Sep 30:izag179. doi: 10.1093.
   PubMed         Abstract available
   
   
6. GOLD SL, Tiao J, Plietz M, Hahn S, et al
   Postoperative weight trajectories after ileal pouch-anal anastomosis are associated with the development of Crohn's-like disease of the pouch.
   Inflamm Bowel Dis. 2026 Sep 29:izag183. doi: 10.1093.
   PubMed        
   
   
7. HIRAI F, Matsuoka K, Watanabe K, Hokari R, et al
   Effectiveness, safety, and clinical outcomes of treatment with the oral alpha4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study).
   Inflamm Bowel Dis. 2026 Sep 28:izag194. doi: 10.1093.
   PubMed         Abstract available
   
   
8. HERRERA-DEGUISE C, Varela E, Alonso VR, Ayala LM, et al
   Fecal calprotectin changes after polyethylene glycol bowel preparation in patients with ulcerative colitis in remission.
   Inflamm Bowel Dis. 2026 Sep 26:izag193. doi: 10.1093.
   PubMed         Abstract available
   
   
9. KIM RS, Li R, Callison E, Froehl L, et al
   Incidence, risk factors, and treatment patterns of pouchitis in pediatric ulcerative colitis.
   Inflamm Bowel Dis. 2026 Sep 26:izag191. doi: 10.1093.
   PubMed         Abstract available
   
   
10. SUAREZ RG, Bar Or O, Orlanski-Meyer E, Shavit Z, et al
    Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study.
    Inflamm Bowel Dis. 2026;32:1880-1887.
    PubMed         Abstract available
    
    
11. PAN Y, Dunleavy KA, Ananthakrishnan AN
    Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis.
    Inflamm Bowel Dis. 2026;32:1910-1918.
    PubMed         Abstract available
    
    
12. SACHDEVA K, Manik D, Chhibba T, Ananthakrishnan A, et al
    Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis.
    Inflamm Bowel Dis. 2026;32:2050-2060.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

13. SPENCER EA, Buck Q, Collen LV, Stein R, et al
    Real-world effectiveness and safety of risankizumab induction and maintenance therapy in pediatric patients with Crohn's disease: a multicenter retrospective analysis.
    J Crohns Colitis. 2026;20:jjag134.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

14. TSURUTA Y, Furuta Y, Nakashima M, Pan C, et al
    Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis.
    J Gastroenterol. 2026 Sep 28. doi: 10.1007/s00535-026-02506.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

15. SHANG L, Yin R, Mao L, Zhen Q, et al
    Influencing factors of health-related productivity loss among patients with inflammatory bowel disease in paid employment based on the theory of social ecosystem: a mixed-methods study.
    Minerva Gastroenterol (Torino). 2026 Sep 29. doi: 10.23736/S2724-5985.26.04003.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum